<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NABUMETONE</span><br/>(na-bu-me'tone)<br/><span class="topboxtradename">Relafen<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic, nsaid</span>; <span class="classification">antipyretic</span><br/><b>Prototype: </b>Ibuprofen<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 750 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Blocks prostaglandin synthesis by inhibiting cyclooxygenase, an enzyme that converts arachidonic acid to precursors of prostaglandins.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antiinflammatory, analgesic, and antipyretic effects. Inhibits platelet aggregation and prolongs bleeding time but does not
         affect prothrombin or whole blood clotting times. Cross-sensitivity with aspirin and other nonsteroidal antiinflammatory drugs
         has been reported.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Rheumatoid arthritis and osteoarthritis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients in whom urticaria, severe rhinitis, bronchospasm, angioedema, or nasal polyps are precipitated by aspirin or other
         <small>NSAID</small>s; active peptic ulcer; bleeding abnormalities. Safety during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension, history of GI ulceration, impaired liver or kidney function, chronic kidney failure, cardiac decompensation,
         patients with SLE.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Rheumatoid &amp; Osteoarthritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1000 mg/d as a single dose, may increase (max: of 2000 mg/d in 12 divided doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food, milk, or antacid (if prescribed) to reduce the possibility of GI upset.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span> Diarrhea, abdominal pain, nausea, dyspepsia, flatulence, melena, ulcers, constipation, dry mouth, gastritis. <span class="typehead">CNS:</span> Tinnitus, dizziness, headache, insomnia, vertigo, fatigue, diaphoresis, nervousness, somnolence. <span class="typehead">Skin:</span> Rash, pruritus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May attenuate the antihypertensive response to <span class="classification">diuretics</span>. <span class="classification">nsaid</span>s increase the risk of <b>methotrexate</b> toxicity. <span class="typehead">Food:</span> Food may increase the peak but not the overall absorption of nabumetone. <span class="typehead">Herbal:</span> <b>Feverfew,</b> <b>garlic,</b> <b>ginger,</b> <b>ginkgo</b> may increase bleeding potential. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; approximately 35% is converted to its active metabolite on first pass through the liver. <span class="typehead">Onset:</span> 13 wk for antirheumatic action. <span class="typehead">Peak:</span> 36 h. <span class="typehead">Distribution:</span> 99% protein bound; distributes into synovial fluid. <span class="typehead">Metabolism:</span> Metabolized in liver to its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). <span class="typehead">Elimination:</span> 80% of dose is excreted in urine as 6MNA; 10% excreted in feces. <span class="typehead">Half-Life:</span> 24 h (6MNA). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain baseline and periodic evaluation of Hgb and Hct levels with prolonged or high-dose therapy.</li>
<li>Monitor for signs and symptoms of GI bleeding.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use caution with hazardous activities since nabumetone may cause dizziness, drowsiness, and blurred vision.</li>
<li>Report abdominal pain, nausea, dyspepsia, or black tarry stools.</li>
<li>Be aware that alcohol and aspirin will increase the risk of GI ulceration and bleeding.</li>
<li>Notify your physician if any of the following occur: persistent headache, skin rash or itching, visual disturbances, weight
            gain, or edema.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>